Workflow
第一医药: 上海市金茂律师事务所关于上海第一医药股份有限公司2024年年度股东大会的法律意见书

Core Viewpoint - The legal opinion letter confirms the legality and validity of the procedures, qualifications, proposals, and voting results of the 2024 annual general meeting of Shanghai First Pharmaceutical Co., Ltd. [1][5] Group 1: Meeting Organization - The 2024 annual general meeting is scheduled for June 20, 2025, at the third meeting room on the 20th floor of 681 Xiaomuqiao Road, Xuhui District, Shanghai [1][2] - The meeting was announced on May 31, 2025, on the Shanghai Stock Exchange website, detailing the time, location, agenda, attendees, registration methods, and voting procedures [2][3] Group 2: Meeting Attendance - A total of 2 shareholders and their representatives attended the meeting, holding 100,278,034 shares with voting rights, which represents a significant portion of the total voting shares [3][4] - Additionally, 116 shareholders participated through the online voting system during the designated trading hours on June 20, 2025 [4] Group 3: Meeting Proposals - The meeting included several key proposals such as the 2024 Board of Directors' work report, 2024 Supervisory Board's work report, financial reports, profit distribution plan, and various resolutions regarding board member elections and compensation [4][5] - Proposals related to the financial service agreement with Bailian Group and the cancellation of the Supervisory Board were also discussed [4] Group 4: Voting Procedures and Results - The voting results indicated that proposals requiring a two-thirds majority were approved, while others needed a simple majority, with specific votes counted separately for minority investors [5] - The legal opinion confirms that all voting procedures and results comply with relevant laws and regulations, ensuring the legitimacy of the meeting outcomes [5]